Health insurers are ending coverage of GLP-1 weight loss drugs.

What it means

Health insurers are ending coverage of GLP-1 receptor agonist drugs (such as Ozempic, Wegovy, and Zepbound) used for weight loss, driven by their high cost. The Vox explainer examines why this is happening and the impact on patients who rely on these medications.

Accuracy & sourcesGrounded

The claim is well-supported by multiple independent news outlets (ABC News, SHRM, WGBH) and insurer announcements (e.g., Cigna confirmed dropping coverage for its own employees). The Vox piece is a secondary explainer that synthesizes these reports without citing a single primary source, but the trend itself is broadly documented.

How new

Genuinely new; the Vox article was published on October 15, 2026, and the trend of insurers dropping GLP-1 coverage has been reported in recent weeks.

Go deeper